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Abstract
Background: Celiac disease (CD) is a frequent inflammatory intestinal disease, with a genetic background, caused
by gliadin-containing food. Some gliadin peptides are not digested by intestinal proteases and can have different
biological effects. Gliadin peptides can induce innate and adaptive T cell-mediated immune responses. The major
mediator of the stress and innate immune response to gliadin peptides (i.e., peptides 31–43 and 31–55) is
the cytokine interleukin-15 (IL-15). Other peptides such as the 33 mer containing the P57–68 sequence, after
tissue transglutaminase deamidation, are well presented to T cell in the intestine and can induce an adaptive
immune response.
Findings: In this paper, we review the recent studies on the digestion of gliadin and the peptides released
by the digestion process. We will also discuss the mechanisms responsible for the internalization and transcytosis of
indigested gliadin peptides in the intestinal epithelium.
Conclusions: Gliadin is not completely digested by the intestinal proteases producing bioactive peptides that have
different biological effects. These peptides are internalized in the cells by an active process of endocytosis and can
traverse the intestinal mucosa with different kinetics and immunological effects. In vivo findings will also be discussed.
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Background
Celiac disease (CD) is a common enteropathy induced
by ingestion of wheat gluten proteins and related prola-
mins from oat, rye, and barley in genetically susceptible
individuals. The genetic predisposition is characterized
by the presence of human leucocytes antigen (HLA)-DQ2
and HLA-DQ8 molecules in virtually all CD patients [1].
The main toxic components of gluten belong to a family
of closely related proline- and glutamine-rich proteins
called gliadin. This is a heterogeneous mixture of pro-
teins that can be assigned to three major groups (i.e.,
α/β-, γ-, and ω-gliadins) [2]. The high percentage of
proline residues makes gliadin resistant to gastric–pancre-
atic and intestinal digestive proteases, so that long gliadin
fragments can reach high concentration levels in the gut
epithelium [3, 4].
To date, a very high number of gluten peptides, deriv-
ing from α- and γ-gliadins, and recently from glutenins,
have been reported to stimulate cluster of differentiation
4 (CD4)+ T lymphocytes isolated from the small intes-
tinal mucosa of CD patients [1]. Although at least 50 T
cell stimulatory gluten epitopes in native or deamidated
form have been identified, the 33-mer peptide is consid-
ered the most immunogenic including six overlapping
epitopes. The 33-mer peptide, released from recombin-
ant α2-gliadin (Swiss-Prot accession number: Q9M4L6)
through gastric–pancreatic enzyme digestion, is highly
resistant to further digestion by intestinal brush border
enzymes (brush border membranes (BBM)) [5]. Hence,
it has been suggested that the 33-mer could reach the
underlying lamina propria (LP) and, following deamida-
tion, can play a central role in the pathogenic cascade of
CD by activating the adaptive immune response.
More recently, attention has been directed to the pos-
sible involvement of innate immune mechanisms in CD
[4]. In particular, it has been showed that the synthetic
peptide α-gliadin 31–43 (LGQQQPFPPQQPY) is able to
up-regulate the expressions of interleukin (IL)-15 on
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CaCo-2 cells surface-induced epithelial cell proliferation
and IL-6 production [4]. The sequence 31–43 is com-
prised of a larger peptide 25 mer (P31–55) together with
the slightly longer P31–49 have been deeply studied in
the last years [4].
These observations indicate that in addition to its in-
teractions with dendritic cells and T lymphocytes of the
lamina propria, gliadin has a dual effect on the intestinal
epithelium of CD patients, both activating the innate
and the adaptive immune response through a different
set of gliadin peptides.
In the present study, we will review the recent litera-
ture about how these active gliadin peptides can be gen-
erated by digestion and mainly how they are transported
in the enterocytes and through the epithelium in vitro
and ex vivo systems.
Gliadin peptides digestion
Gliadin is a protein difficult to digest [5]. Several studies
have approached the issue of gliadin digestibility in differ-
ent systems. Recent studies have considered the digestion
of a recombinant α-gliadin Q9ZP09. The in vitro digests
of the recombinant protein produced a number of pep-
tides, but supplementation with BBM greatly simplified
the digests leaving two main peptides, the 25-mer peptide
31–55 and the 33-mer. Incubation of the synthetic 25 mer
with BBM enzymes for longer reaction times confirmed
its high resistance to proteolytic enzymes. Surprisingly, in
the same system, the immuno-active epitope for the adap-
tive T cell-mediated immune response (P56–68), also
included within gliadin Q9ZP09 sequence, was partly
digested by gastric/pancreatic enzymes and completely
digested after BBM supplementation. Indicating that
gliadin Q9ZP09 was extensively hydrolyzed in vitro
while the peptide sequence stimulating the innate
response (P31–55) in CD was unaffected [6]. More
recently, the same group analyzed the digestion of
common pasta (Triticum durum semolina), using a
sophisticated in vitro multi-compartment model that
included oral, gastric, and duodenal phases of digestion
[6]. Interestingly, the digestion of the cooked pasta
showed the persistence of several wheat-derived peptides
identified by liquid chromatography–mass spectrometry
that included a-gliadin 31–55 and the shortened form a-
gliadin 31–43 (Fig. 1). These studies demonstrate that
these gliadin peptides can really come into contact with
the intestinal epithelium in our everyday life and that in
vitro studies using them have a physiologic rationale.
Moreover, these data indicate that digestion of the P31–43
(or -49 or 25-mer) sequence is very difficult, implying that
its biological activity can be central to the CD pathogen-
esis. An immediate application of these observation would
be to find cereals that are deprived of the most indigested
peptides to use in the CD patients diet or to find ways to
process gluten-containing produces as to render them
deprived of the host-indigested peptides.
Gliadin peptides P31–43 and P57–68 enter the cells by an
active process
Gliding peptides enter the cells by endocytosis. In fact,
their entrance into the cells requires 37 °C temperature
and Ca++ in the media [7]. Experiments with an inhibitor
of endocytosis (methyl-β-cyclodextrin, M-β-CD) reduced
the entrance of P31–43 labeled with a fluorescent tail such
as lissamine (liss). Interestingly, the entrance of P31–
43-liss was unaffected by filipin, an inhibitor of lipid
raft/caveolae-mediated endocytosis. The opposite effect
was generated by these inhibitors on P57–68-liss, indi-
cating that both peptides enter intestinal epithelial cells
by endocytosis, but only P57–68 enter the cells by lipid
raft/caveolae-mediated endocytosis. Zimmermann et al.
also confirmed the effect of M-β-CD on the entrance
of P31–43 and P57–68-fluorescence labeled in CaCo-2
cells [8]. The fact that a precise way of the entrance of
these peptides has been discovered opens several new
opportunity of finding drugs that can interfere with the
entrance of the indigested gliadin peptides. These dif-
ferences in the route of entrance have to be taken into
Fig. 1 Sequences comparison of gliadin peptides. Twenty-five and 33 mer were the gliadin peptides most resistant to intestinal peptides. Swiss-
Prot accession number, amino acids, and length were shown
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account for future drug interference. Still not answered is
the question how these peptides enter the cells. A receptor
for both gliadin peptides has been looked for but not
found [8]. This is not entirely surprising as many bioactive
peptides in nature do not need a receptor to enter the
cells, as they can interact with the membranes directly [9].
Noteworthy, P31–43, but not P57–68, can interact with a
membrane mimetic environment [10].
Localization of gliadin peptides in the endocytic vesicles
Next, the localization of gliadin peptides in intestinal
epithelial cells has been investigated. Interestingly, both
gliadin peptides P31–43 and P57–68-liss have been lo-
calized in the early compartment of endocytosis in
CaCo-2 cells after 30-min incubation, but only 3 h after
treatment, there is segregation of P41–43/49, but not of
P57–68, in the early endosomal compartment. This
interesting segregation of P31–43 in the early compart-
ment has been demonstrated by different groups and by
different methods, both in epithelial cells in culture and
in intestinal biopsies of CD patients and controls in ex
vivo experiments [11–14].
Biological consequences of P31–43/49 segregation in the
early endocytic compartment
The biological consequences of this segregation can be
several and in different pathways. In fact, P31–49, unlike
P57–67, bypassing HLA-DR-positive late vesicles and es-
caping antigen presentation at the basolateral membrane
cannot stimulate gluten-sensitive T cells [11], preventing
oral tolerance.
Moreover, the segregation in the early compartment of
P31–43 peptide is due to a direct effect of the peptide
on the endocytic trafficking. In fact, P31–43 is strikingly
similar to a region of hepatocyte growth factor-regulated
substrate (HRS) kinase, a key molecule regulating endo-
cytic maturation, which is localized on the membranes
of early endocytic vesicles [13].
The sequence similarity between gliadin peptide P31–43
and HRS is located in a small area of the proline/glutam-
ine-rich domain of HRS. The COOH-terminal of HRS
contains a clathrin-binding domain that binds clathrin to
clathrin-coated vesicles and is one of the domains needed
to localize HRS to the vesicle membranes. Both in CaCo-2
cells and in the celiac enterocytes, P31–43 localizes in the
early endosomes and delays vesicular trafficking of several
different cargos [13]. Endocytosis has many effects on sig-
naling; in fact, signaling pathways and endocytic pathways
are regulated in a reciprocal manner. Consequently, endo-
cytosis affects several cell functions, ranging from prolifer-
ation to actin organization, cell motility, and stress/innate
immunity activation. Gliadin peptide P31–43 can increase
IL-15, one of the major effectors of innate immunity in
CD on CaCo-2 cell surface, not affecting mRNA or
protein levels, but increasing the recycling of the complex
IL-15/IL-15 receptor alpha to the membrane [4, 15, 16].
Biological effects of gliadin peptide P31–43 have been
recently reviewed [4]. Notably, impairment of the protein
targeting and function has been described also when
Frazer’s fraction of gliadin has been used, due to an inter-
action with the actin cytoskeleton [17, 18].
The block in the early compartment of gliadin peptides
P31–43 or 49 can be overcome by cholera toxin B [12], by
CD patients serum [19], or by linking the peptide to biotin
[20]. Strikingly, even when forced into the late compart-
ment by biotin, for example, this peptide has some
important biological effects on cellular stress and inflam-
mation [20].
Other composts such as antibody against tissue trans-
glutaminase (tTG) [7] or probiotics [21] can prevent glia-
din peptides entrance in the cells, with reduced biological
effects for several read outs, indicating that their entrance
is crucial to the activation of cellular signaling. All to-
gether, these observations indicate that gliadin peptides
P31–43/49 have important biological effects by interfering
with the endocytic pathway. These data suggest that indi-
gested gliadin peptides have strong biological activity not
only by activating the adaptive immune response but also
by initiating at the level of the intestinal epithelium stress/
innate immune response.
Gliadin peptides transcytosis
Few studies are available on the destiny of gliadin pep-
tides after they enter the cells in intestinal biopsies.
Among these, Ménard et al. have established that P31–
49 and 33 mer do enter the epithelial cell of intestinal
biopsies from CD patients by intracellular pathway, ex-
cluding the paracellular entrance [22]. Lebreton et al. have
shown that in active celiac mucosa, gliadin peptides can
be transcytosed from the apical of the intestinal epithe-
lium to the basolateral side together with transferrin and
IgA avoiding the late endocytic compartment. Transcyto-
sis of IgA and transferrin is a well-known phenomenon,
and transferrin increases in proliferating cells. The authors
observe that this transcytosis can be prevented by anti-
bodies against tTG and happens only when IgA–anti-
gliadin and transferrin increase in the intestinal mucosa,
basically when the disease is already in the active phase
[23]. Moreover, Schumann et al. demonstrated that
transcytosis of 33-mer is Ras-related in brain (Rab 5)
dependent (Rab 5 is a marker of the early endocytic
compartment) and higher in active CD, than in patients
on a gluten-free-diet and in controls [15]. What hap-
pens to transcytosis of gliadin peptides before the
disease is manifested is not known. On the other side,
transcytosis of gliadin peptides in in vitro systems such
as CaCo-2 cells strongly depends on the length of the
peptides and integrity of the epithelial barrier [5, 6, 8].
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Moreover, these observations decidedly exclude the
possibility that gliadin peptides enter by a paracellular
pathway and, although these data have been published
several years now, this notion is still pointlessly de-
bated in the field.
In vivo findings
In vivo findings about viability of gliadin peptides are
very scarce. One interesting paper on the detection of
gliadin peptide 33 mer in the feces of CD patients on a
GFD fed with known amount of gliadin [24] indicates
that 33-mer gliadin peptide is undigested by the intes-
tinal brush border in vivo. Moreover, in a monkey model
of gluten sensitivity, 33-mer peptide can be detected in
the serum when the disease starts, indicating that this
peptide can trespass the mucosa intact in vivo [25]. No
reports are present in the literature about the 25 mer (or
31–43/55) in vivo. The detection of indigested peptides
in the feces can be used as a marker of diet complaint, a
test that can be very useful in cases of doubt or for the
monitoring of adolescent diet.
Conclusions
Although the study of gliadin peptides trafficking is an
important way to understand the mechanisms of CD,
many questions still have to be answered mainly regard-
ing the specificity of the effects of gliadin peptides in CD
cells and intestinal epithelium. Why gliadin peptides are
so toxic for celiac disease patients? Is there a constitutive
defect in CD cells that renders them more sensitive to
gliadin peptides effects? Are they toxic in control cells?
Is prevention of entrance of gliadin peptides in the epi-
thelium enough to prevent the disease? Future study will
be able to answer these questions.
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